Parkinson's disease
Neurology · 2008–2024
14decisions
11medicines
4carried consumer input
7individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| levodopa with carbidopa monohydrate and entacapone Advanced idiopathic Parkinson's disease with severe motor fluctuations despite optimised alternative pharmacological treatment. | Jul 2024 | Recommended with restriction | 2 individuals |
| foslevodopa with foscarbidopa Advanced Parkinson's disease with severe disabling motor fluctuations not adequately controlled by oral therapy. | May 2024 | Not recommended | input received Hospital Research Foundation Group · Movement Disorder Society |
| foslevodopa with foscarbidopa Treatment of advanced Parkinson's disease with severe disabling motor fluctuations not adequately controlled by oral therapy. | Nov 2024 | Recommended | 3 individuals |
| levodopa with carbidopa and entacapone Advanced idiopathic Parkinson's disease with severe motor fluctuations despite optimised alternative pharmacological treatment. | Nov 2024 | Noted | 2 individuals |
| apomorphine Extension of current listing for maintenance treatment of Parkinson's disease following initiation in a hospital setting, to include General Schedule Authority… | Nov 2020 | Recommended with restriction | none received |
| levodopa with carbidopa monohydrate Advanced Parkinson's disease with severe disabling motor fluctuations not adequately controlled by oral therapy. | Nov 2019 | Recommended with restriction | none received |
| apomorphine hydrochloride hemihydrate Treatment of Parkinson's disease in patients with severely disabling motor fluctuations that have not responded to other therapy. | Jul 2018 | Recommended | none received |
| apomorphine hydrochloride Treatment of Parkinson's disease in patients with severely disabling motor fluctuations which have not responded to other therapy. | Mar 2018 | Recommended with restriction | unclear |
| safinamide Add-on therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations. | Nov 2018 | Recommended with restriction | none received |
| apomorphine Treatment of Parkinson's disease in patients with severely disabling motor fluctuations refractory to conventional therapy. | Jul 2016 | Recommended with restriction | no section in document |
| levodopa with carbidopa Advanced Parkinson's disease with severe disabling motor fluctuations not adequately controlled by oral therapy. | Nov 2016 | Recommended | none received |
| rasagiline as adjunctive therapy in patients being treated with levodopa-decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to… | Jul 2011 | Recommended | unclear |
| levodopa with carbidopa Advanced idiopathic Parkinson's disease with severe motor fluctuations despite optimised oral treatment, administered via intestinal gel infusion for patients… | Mar 2008 | Not recommended | no section in document |
| rotigotine Monotherapy or in combination with levodopa for the treatment of idiopathic Parkinson's disease from early stage to advanced disease. | Mar 2008 | Recommended | no section in document |
Who spoke
Hospital Research Foundation Group · Movement Disorder Society
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.